PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.

Taken together, our data points to a putative role for PD-L1 expression in glioblastoma biology, which correlates to poor patient overall survival, as well as with a general systemic inflammatory status and immunosuppression.